Lumera Announces New Podcast Interview with Dr. Charles Campbell; Next in 2007 Lumera Experts Series
June 27 2007 - 10:30AM
Business Wire
Lumera Corporation (NASDAQ: LMRA), a leader in the emerging field
of nanotechnology, announced an interview with Dr. Charlie Campbell
as the most recent installment of its 2007 Lumera Experts
Podcasting Series. Campbell is a Professor of Chemistry and
founding co-director of the Center of Nanotechnology at the
University of Washington as well as a member of Lumera�s Scientific
Advisory Board. The Department of Chemistry at the University of
Washington is the third highest funded public institution in
chemical research. As a faculty member, Dr. Campbell and others saw
the need to converge their research on the nanoscale, which led to
the founding of the Center of Nanotechnology. The Center has
enabled better research and education in the field of
nanotechnology, which is the wave of the future. �There are huge
global issues that are pushing fast such as the fear of global
warming and energy sources drying-up in the middle east, so there
is a need to push for new energy sources in nanotechnology,� said
Campbell in his podcast interview. �The research infrastructure for
making new materials that occurred in the field of nanotechnology
in about the past ten years will enable some very important
technological breakthroughs in this area.� �Lumera is very
fortunate to have Dr. Campbell as a member of Lumera�s Scientific
Advisory Board, because of his leading expertise in
nanotechnology,� commented Lumera Chief Executive Officer Tom Mino.
�We are very excited about the progression in our products that are
helping to speed research in many areas of science. We will
continue to work closely with experts such as those featured in our
podcast series, to ensure that our company stays at the forefront
of this exciting field.� �Lumera is making exciting progress with
their product that allows 1500 micro sensors to simultaneously
interrogate and find solutions of chemical interests,� said
Campbell in his podcast interview. �It promises to be a very
powerful tool for future research and an area of importance for
society�s impact on medicine.� Earlier this year, Lumera announced
the 2007 Lumera Experts Podcast Series featuring interviews with
industry leaders who are familiar with Lumera�s technology and are
experts in nanotechnology, bio-arrays, drug discovery,
electro-optics, and wireless technologies. Podcast interviews by
the following individuals have all been previously featured as part
of the series and are currently available to download on Lumera�s
website: Dr. Niro Ramachandran, a research associate at the Harvard
Institute of Proteomics led by Dr. Josh LaBaer Dr. Larry Dalton, a
Professor of Chemistry and Electrical engineering at the University
of Washington and Nobel Prize Nominee Dr. Joseph Vallner, recently
President and CEO of Capnia Tom Mino, CEO of Lumera Dr. Sam
Gambhir, professor of radiology and bioengineering, Director of the
Molecular Imaging Program and head of the nuclear medicine division
at Stanford University Dr. Jonathan Wells, Principal Partner at
AJIS LLC, a broadband wireless technology consultancy and recently
Director of Product Management and International Regulatory Affairs
for GigaBeamhave The podcasts are available through a variety of
distribution networks and can be downloaded among other places at
podtech.com; Apple�s iTunes, Rocky Mountain Podcasting and at
Lumera�s own website, http://www.lumera.com/Company/Podcasts.php.
About Lumera Lumera is a leader in the emerging field of
nanotechnology. The company designs proprietary molecular
structures and polymer compounds for the bioscience and
communications/computing industries, both of which represent large
market opportunities. The company also has developed proprietary
processes for fabricating such devices. For more information,
please visit www.lumera.com. Certain statements contained in this
release are forward-looking statements that involve a number of
risks and uncertainties. Factors that could cause actual results to
differ materially from those projected in the company's
forward-looking statements include the following: market acceptance
of our technologies and products; our ability to obtain financing;
our financial and technical resources relative to those of our
competitors; our ability to keep up with rapid technological
change; government regulation of our technologies; our ability to
enforce our intellectual property rights and protect our
proprietary technologies; the ability to obtain additional contract
awards and to develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical
milestones in key products; and other risk factors identified from
time to time in the company's SEC reports, including its Annual
Report on Form 10-K, and its Quarterly Reports on Form 10-Q.
Lumera (NASDAQ:LMRA)
Historical Stock Chart
From Jul 2024 to Aug 2024
Lumera (NASDAQ:LMRA)
Historical Stock Chart
From Aug 2023 to Aug 2024